FY2025 EPS Estimate for Delcath Systems Reduced by Analyst

Delcath Systems, Inc. (NASDAQ:DCTH) – HC Wainwright lowered their FY2025 EPS estimates for shares of Delcath Systems in a note issued to investors on Wednesday, November 5th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.06 for the year, down from their previous forecast of $0.13. HC Wainwright has a “Buy” rating and a $30.00 price target on the stock. The consensus estimate for Delcath Systems’ current full-year earnings is ($0.79) per share. HC Wainwright also issued estimates for Delcath Systems’ Q4 2025 earnings at ($0.06) EPS, Q2 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.27 EPS and FY2028 earnings at $1.77 EPS.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Tuesday, November 4th. The company reported $0.02 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.02. The firm had revenue of $20.56 million during the quarter, compared to the consensus estimate of $23.22 million. Delcath Systems had a net margin of 3.18% and a return on equity of 6.91%.

A number of other equities research analysts have also commented on DCTH. BTIG Research reiterated a “buy” rating and issued a $23.00 price target on shares of Delcath Systems in a research report on Tuesday. Weiss Ratings restated a “hold (c-)” rating on shares of Delcath Systems in a report on Wednesday, October 8th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $21.00 price objective on shares of Delcath Systems in a research note on Tuesday, October 21st. Craig Hallum reissued a “buy” rating and set a $20.00 target price on shares of Delcath Systems in a research note on Tuesday, October 21st. Finally, Stephens dropped their target price on shares of Delcath Systems from $25.00 to $18.00 and set an “overweight” rating on the stock in a report on Wednesday. Five equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $22.40.

Delcath Systems Stock Down 0.5%

NASDAQ DCTH opened at $8.64 on Friday. The company has a market capitalization of $302.24 million, a price-to-earnings ratio of 172.80 and a beta of 0.81. Delcath Systems has a twelve month low of $8.39 and a twelve month high of $18.23. The stock has a fifty day simple moving average of $10.79 and a 200 day simple moving average of $12.28.

Hedge Funds Weigh In On Delcath Systems

A number of institutional investors and hedge funds have recently made changes to their positions in DCTH. Cibc World Market Inc. increased its position in Delcath Systems by 21.8% in the 3rd quarter. Cibc World Market Inc. now owns 178,510 shares of the company’s stock valued at $1,919,000 after buying an additional 31,900 shares in the last quarter. Simplify Asset Management Inc. increased its holdings in shares of Delcath Systems by 144.9% during the third quarter. Simplify Asset Management Inc. now owns 261,126 shares of the company’s stock valued at $2,807,000 after acquiring an additional 154,497 shares in the last quarter. Capital Advisors Wealth Management LLC increased its holdings in shares of Delcath Systems by 12.5% during the third quarter. Capital Advisors Wealth Management LLC now owns 85,500 shares of the company’s stock valued at $919,000 after acquiring an additional 9,500 shares in the last quarter. Nomura Holdings Inc. acquired a new position in shares of Delcath Systems during the second quarter worth approximately $324,000. Finally, Tower Research Capital LLC TRC bought a new position in shares of Delcath Systems in the 2nd quarter worth $40,000. Institutional investors own 61.12% of the company’s stock.

About Delcath Systems

Delcath Systems, Inc, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company’s lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.